Highlights include:
• VivoMedica and Cellular Dynamics International (CDI) presented new DrugPrint® data on the use of the DrugPrint® system with hSC-derived human cardiomyocytes at the recent Safety Pharmacology Society conference in Madison WI, USA. • New DrugPrint® data presented at the 6th International Conference on Substrate-Integrated micro-electrode arrays (MEA) in Reutlingen, Germany • Expansion of DrugPrint® into human Stem Cells (hSC) through a collaboration agreement with Cellartis AB to explore the combination of hSC and the sophisticated analytical capabilities of the DrugPrint® system • PathScoreTM partners shortlisted • Partnership discussions for potential PathScoreTM sub-licensees at an advanced stage
Commenting on the interim results, CEO Peter Leyland said:
“At the beginning of the year we set out with clear strategic goals that would lead to increasing the value of VivoMedica. These were to continue the development and enhance commercial interest in DrugPrint® particularly through collaboration with the leading hSC providers from around the world; to identify and collaborate with a leading global partner to commercialise the PathScoreTM technology. I am pleased to report at this time of our interim results that we are on track with all these goals and we look forward to reporting on further progress.”
For further information, please contact:
Buchanan Communications Tim Anderson / Catherine Breen 020 7466 5000
Brewin Dolphin Investment Banking (NOMAD) Mark Brady / Alison Barrow 0845 270 8600
